Status:
RECRUITING
Methylene Blue for the Treatment of Septic Shock
Lead Sponsor:
Northern Jiangsu People's Hospital
Conditions:
Septic Shock
Eligibility:
All Genders
18-90 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of methylene blue among adult patients with septic shock.
Detailed Description
Septic Shock is a leading cause of morbidity and mortality in critically ill patients worldwide. A potential benefit of methylene blue in the treatment of septic shock has recently been described by ...
Eligibility Criteria
Inclusion
- age 18 years old or older;
- diagnosis of septic shock within 12 h.
Exclusion
- recent intake (4-weeks) of selective serotonin re-uptake inhibitors;
- pregnant;
- definitive pulmonary hypertension or chronic pulmonary heart disease;
- known glucose-6 phosphate dehydrogenase (G-6PD) deficiency;
- known allergy to methylene blue, phenothiazines, or food dyes;
- anticipated death from a preexisting disease within 90 days after randomization (as determined by the enrolling physician);
- refusal of the attending staff or patient family;
- participated in other study.
Key Trial Info
Start Date :
August 5 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT06532240
Start Date
August 5 2024
End Date
January 1 2026
Last Update
January 6 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northern Jiangsu people's hospital
Yangzhou, Jiangsu, China, 225000